DarioHealth Corp (DRIO)

[PennyStockTrader2]

Continuing to persevere on DARIO, this one will have its day bigtime:

"We are already seeing first results with significant contracts and we believe that in the second half of this year we will see things manifest a significant increase in sales"

https://www.bizportal.co.il/investors-club/news/article/780445

[PennyStockTrader2]

https://medcitynews.com/2020/04/fda-oks-digital-health-tools-for-use-during-pandemic/

[PennyStockTrader2]

MedCity News DRIO Feature article


"What sets it apart from competitors is DarioHealth has created a glucometer that plugs directly into users’ smartphones, automatically recording their results."

https://medcitynews.com/2020/03/dariohealth-goes-after-self-insured-market-with-new-partnership/

[PennyStockTrader2]

dario health stay safe

https://www.linkedin.com/posts/dariohealth_drio-dariohealth-staysafe-activity-6644247394324094976-Uc31

[Ganzo9191]

https://www.google.com/amp/s/www.proactiveinvestors.com/companies/amp/news/912889

[ClayTrader]

* * $DRIO Video Chart 12-03-2019 * *

Link to Video - click here to watch the technical chart video

[PennyStockTrader2]

These pennies all have their day or days in the sun, and this was one of them. I was able to make nice sales from the 9s up to 11.25, and have started buying back in lower quantity down to 7.10. If it falls further I buy more, if it rallies over 9.50 I sell carefully. Reminds me so so much of Precipio which is also poised to have its next day in the sun. Long term I have said its a buy, just never dreamed it would ever fall as low as it has. Just look at the market cap compared to longovo or whatever the name of that other stock is in the same space, makes DRIO look so so undervalued.

[europtiger]

And out

[europtiger]

8,60,s i mean

[europtiger]

Just got 9,60,s

[crudeoil24]

Walmart is the largest retailer in the world and is the second largest e-commerce retailer in the U.S. It is also an innovator in healthcare, piloting several initiatives such as opening its own Walmart Health centers and creating a Home Health Care section on Walmart.com.

The Dario digital diabetes app is among the most downloaded and highest rated healthcare apps, with a 4.9/5.0 star rating and over 8,000+ reviews on the Apple store. Its Net Promoter Score (NPS), a measure of willingness of customers to recommend a company's products or services to others, is +77, considered "world class" and the highest in its category, on a -100 - +100 scale.

"Walmart strives to offer its shoppers health solutions that will help them manage their own health in the most efficient way possible. We are excited to access Walmart's online distribution channel given the extremely high volume of annual visitors. We will offer Walmart's consumers MyDario™, our complete digital solution to manage diabetes, hypertension, nutrition and exercise. Our system is affordable and supported by a large body of clinical evidence that we believe demonstrates that Dario significantly and quickly improves the health and wellness of its users. We believe that the positive results seen while using our system reinforces engagement and are part of the reason why users rate Dario as one of the best solutions for managing chronic conditions," said Olivier Jarry, DarioHealth's President and Chief Commercial Officer.

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel.

For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company discusses its belief that the existing body of evidence with respect to its system demonstrates that Dario significantly and quickly improves the health and wellness of its users and the belief that the positive results seen while using its system reinforces engagement and are part of the reason why users rate Dario as one of the best solutions for managing chronic conditions, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
[e-mail]
Tel: [phone]



Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/walmart-starts-distributing-the-dariohealth-digital-diabetes-management-system-300968169.html

SOURCE DarioHealth Corp.


Copyright 2019 PR Newswire

[whytestocks]

News: $DRIO Walmart Starts Distributing the DarioHealth Digital Diabetes Management System

BENTONVILLE, Arkansas and NEW YORK , Dec. 3, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader, DarioHealth Corp. (NASDAQ: DRIO) announced today the launch of the Dario-powered digital diabetes program on Walmart.com . Walmart is the largest retailer in t...

In case you are interested DRIO - Walmart Starts Distributing the DarioHealth Digital Diabetes Management System

[1vman]

*****Wow shareholders already down since reverse split ! This is the 3rd R/S issued that's devastated pps

This will bleed back down to the teens again

Nasdaq needs to boot this garbage back to the otc pinks were it belongs


Enough Said !

[ariel50]

Only suckers invest in this company.

[1vman]

*****Another reverse split here !

WOW JUST WOW WHAT A POS STOCK THIS IS


Shareholders are being let to slaughter here by this incompetant managerial team


What a scam !

[jedijazz]

$DRIO .2313 +5.09% Company investor presentation is available at: mydario.investorroom.com/

[1vman]

*****Buyer beware ! Another reverse split_coming_soon_for this junk to remain on the NASDAQ

[jedijazz]

DarioHealth Corporat (DRIO) 0.24755 +0.00745 (3.10%)
Volume: 29,551

[jedijazz]

$DRIO Revenues For Connected Medical Device Market Expected to Reach $6 Billion
https://marketwatch.com/press-release/revenues-for-connected-medical-device-market-expected-to-reach-6-billion-2019-07-30?mod=mw_quote_news

[ProfitScout]

Top Ten Reviews gives DRIO 4.5 out of 4 Stars.
CLICK HERE:
https://www.toptenreviews.com/dario-LC-review

From the review:

OUR VERDICT
The Dario LC Blood Glucose Management System is the ultimate all-in-one device for checking your blood sugar. The unit contains a monitor that plugs directly into your phone, a lancing device and a strip storage. This is the perfect portable setup with smart app support for deep data analysis. Test strips could be more widely available but that's a small gripe.

[ProfitScout]

The DRIO leadership team is shaping up into a top notch company asset that clearly has the experience and capabilities to optimize the potential of the business plan to provide the best in digital technology to a growing list of users worldwide.

DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, has appointed Dr. Abigail Hirsch to its Advisory Board where she will help guide commercial and Business-to-Business (B2B) efforts.

Dr. Hirsch has many years of experience utilizing clinical psychology, data analytics and educational design to create innovative healthcare technology that helps people lead healthier, more fulfilling lives.

Prior to joining Dario, Dr. Hirsch served as Chief Clinical Officer at a behavioral health company called myStrength, helping lead the company from inception through its acquisition by Livongo Health, Inc. in the first quarter of 2019. She holds a Ph.D. in Clinical Psychology from the University of Massachusetts.

[jedijazz]

$DRIO In recent News, Nasdaq's DarioHealth Appoints Digital Therapeutics Pioneer Dr. Abigail Hirsch to Its Advisory Board to Support Commercial Strategy and Execution
https://dariohealth.investorroom.com/2019-10-22-DarioHealth-Appoints-Digital-Therapeutics-Pioneer-Dr-Abigail-Hirsch-to-Its-Advisory-Board-to-Support-Commercial-Strategy-and-Execution

[jedijazz]

$DRIO .2698 +2.98% DarioHealth EPS beats by $0.03 #Nasdaq as DarioHealth Reported Results for Third Quarter 2019 https://marketwirenews.com/news-releases/dariohealth-reports-results-for-third-quarter-2019-7732449942458983.html?i=c

[ProfitScout]

DRIO has been recognized as having the best technology in its field. See the official announcement here:

DarioHealth Corp.@Dario_Health
Following @Dario_Health
Verywell Names @Dario_Health ‘Best of 2019!’ Verywell, a leading health and wellness website, has recognized Dario as having the best 2019 product for data management! Check out why here https://www.verywellhealth.com/best-glucometers-4686590

Twitter Link: https://twitter.com/Dario_Health/status/1179735845

[1vman]

*****So much for the conference call today ! Market just doesn't like the managerial team here period !

PPS is and has been reflecting that sentiment for years now !


Enough Said !

[whytestocks]

News: $DRIO DarioHealth Reports Results for Third Quarter 2019

NEW YORK and CAESAREA, Israel , Oct. 28, 2019 /PRNewswire/  -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today reported financial and operational results for the third quarter ended September 30, 2019 . Q3 2019 Revenues of $1.87 million , a 13...

Find out more DRIO - DarioHealth Reports Results for Third Quarter 2019

[1vman]

*****Buyer beware ! Another reverse split_coming_soon_for this junk to remain on the NASDAQ

[ProfitScout]

Today's financial results for DRIO are impressive and again confirm that management has this company in the right track and is moving the business plan successfully forward in both the immediate time frame and in the long term strategic perspective.

Note the comments from the company's CEO in the news:

CEO, Erez Raphael, stated, "In the third quarter, we believe that we produced tangible evidence that broadening our focus from the direct-to-consumer (D2C) channel alone to include the B2B channel is working well. We grew Dario's top-line while significantly improving gross margins and reducing losses. This quarter's performance also highlights the potential of our high margin SaaS oriented membership program. As previously mentioned, the resulting benefits of this B2B channel focus are measurable in terms of larger patient adoption, more certain revenue streams and lower customer acquisition costs.

[StockHighAlert-]

$DRIO will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on October 28, 2019 at 9:00 AM Eastern Time.

To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/C-E2275A48A64BC

[jedijazz]

$DRIO Financial Results for the Nine Months Ended September 30, 2019:

Revenue for the nine months ended September 30, 2019 was $5.76 million, a 1.2% increase from $5.69 million for the nine months ended September 30, 2018.

Gross profit of $1.76 million was recorded for the nine months ended September 30, 2019, an increase of 14%, or $215,000, compared to gross profit of $1.54 million for the nine months ended September 30, 2018.

Operating loss for the nine months ended September 30, 2019 increased by $762,000 to $13.5 million, compared to a $12.8 million operating loss for the nine months ended September 30, 2018.

Net loss attributable to holders of common stock increased by $743,000 to $13.56 million for the nine months ended September 30, 2019, as compared to $12.82 million for the nine months ended September 30, 2018.

Non-GAAP billings for the nine months ended September 30, 2019 were $6.34 million, a 4.2% increase from $6.08 million in the nine months ended September 30, 2019. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."

A Company investor presentation is available at: http://mydario.investorroom.com/

[StockHighAlert-]

CEO, Erez Raphael, stated, "In the third quarter, we believe that we produced tangible evidence that broadening our focus from the direct-to-consumer (D2C) channel alone to include the B2B channel is working well. We grew Dario's top-line while significantly improving gross margins and reducing losses. This quarter's performance also highlights the potential of our high margin SaaS oriented membership program. As previously mentioned, the resulting benefits of this B2B channel focus are measurable in terms of larger patient adoption, more certain revenue streams and lower customer acquisition costs.

In July 2019, Dario successfully launched a U.S. Food and Drug Administration cleared hypertension extension of its chronic disease management platform. We're excited about the versatility of our platform and that we can now potentially help 75 million patients in the U.S. who suffer from this condition. We've received initial positive feedback from existing users about their ability to manage both diabetes and hypertension on our digital platform and we are excited to offer our technology to address an additional potential large market opportunity.

In September 2019, Dario announced its first strategic partnership with a private company, Dance Biopharm Holdings, Inc. Dario's platform will be integrated with Dance's smart inhaler to provide patients with automated, real-time treatment data through our advanced mobile application. This partnership may generate revenues in 2020 and beyond. We believe this partnership will be the first of many as we seek to combine our technology with other therapeutic, device and service offerings. We believe this highlights the compatibility and versatility of Dario's digital chronic condition management platform to integrate with other devices to assist in managing other diseases.

Finally, we continued to win new clients and increase the pipeline of payers, employers, and providers who want an integrated solution that provides value and accountability driven healthcare, enabled by Dario's user-centric and evidence-based platform.

Management's continued acceptance of a portion of its compensation in shares is another ongoing contributor to a reduced cash burn and a reflection of our management's belief in Dario's future.

As we assess the global healthcare market and Dario's place in it, we are confident that we have built a platform technology which will deliver better care at a lower cost for patients with chronic diseases.

[StockHighAlert-]

Financial Results for the Three Months Ended September 30, 2019:

Revenue for the third quarter ended September 30, 2019 was $1.87 million, a 13% sequential increase over Q2 2019 and a 0.6% decrease from $1.88 million in the third quarter ended September 30, 2018.

Gross profit of $873,000, representing 46.7% of revenues, was recorded for the three months ended September 30, 2019, an increase of 86%, or $405,000, compared to gross profit of $468,000 for the three months ended September 30, 2018.

Operating loss for the three months ended September 30, 2019 decreased by $1.25 million to $2.8 million, as compared to a $4.5 million operating loss for the three months ended September 30, 2018.

Net loss attributable to holders of common stock decreased by $1.26 million to $2.8 million for the three months ended September 30, 2019, as compared to $4.1 million for the three months ended September 30, 2018.

Our new B2B focus has allowed us to be more efficient with our use of cash, extending our runway of existing balance sheet resources.

As of September 30, 2019, cash and cash equivalents totaled approximately $4.6 million.

Non-GAAP billings for the three months ended September 30, 2019 were $1.78 million, a 20% decrease from $2.2 million in the three months ended September 30, 2019. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."

[StockHighAlert-]

Financial Results for the Nine Months Ended September 30, 2019:

Revenue for the nine months ended September 30, 2019 was $5.76 million, a 1.2% increase from $5.69 million for the nine months ended September 30, 2018.

Gross profit of $1.76 million was recorded for the nine months ended September 30, 2019, an increase of 14%, or $215,000, compared to gross profit of $1.54 million for the nine months ended September 30, 2018.

Operating loss for the nine months ended September 30, 2019 increased by $762,000 to $13.5 million, compared to a $12.8 million operating loss for the nine months ended September 30, 2018.

Net loss attributable to holders of common stock increased by $743,000 to $13.56 million for the nine months ended September 30, 2019, as compared to $12.82 million for the nine months ended September 30, 2018.

Non-GAAP billings for the nine months ended September 30, 2019 were $6.34 million, a 4.2% increase from $6.08 million in the nine months ended September 30, 2019. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."

A Company investor presentation is available at: http://mydario.investorroom.com/

[StockHighAlert-]

Q3 2019 Revenues of $1.87 million, a 13% sequential increase over Q2 2019, and a 0.6% decrease compared to Q3 2018

Q3 2019 Gross Profit of $873,000, representing 46.7% of revenues, a sequential increase of 168% over Q2 2019, and an 86% increase over Q3 2018

Operating Loss in Q3 2019 decreased by $1.25 million to $2.8 million, a sequential decline of 48% compared to Q2 2019 and a 31% decrease compared to Q3 2018

Dario demonstrated strategic interest in its platform with potential revenue generating possibly beginning in the first half of 2020, Dance Biopharma partnership and exciting pipeline of potential additional opportunities

Results reflect and support Dario's strategic push into business-to-business (B2B), as sequential revenue growth and client wins were generated in combination with a lower expense structure

[StockHighAlert-]

$DRIO today reported financial and operational results for the third quarter ended September 30, 2019. https://finance.yahoo.com/news/dariohealth-reports-results-third-quarter-102900329.html

[jedijazz]

Conference call less than a week away ProfitScout! The live call can be accessed by dialing 1-844-369-8770 or 1-862-298-0840 (international).

Participants should ask for the DRIO DarioHealth Earnings Conference Call.

The conference call will also be available via live webcast at: https://www.investornetwork.com/event/presentation/54487

Conference Call Details:

Date: Tuesday, October 28, 2019

Time: 9:00am EDT

[ProfitScout]

DarioHealth to Host Third Quarter 2019 Conference Call October 28, 2019

Earnings Discussion and Business Update Scheduled for 9:00 am EDT

NEW YORK and CAESAREA, Israel, Oct. 17, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (DRIO) today announced it will release its third quarter 2019 results on Monday, October 28, and host a conference call the same morning at 9:00 am EDT.

The Company will discuss its third quarter 2019 operating and financial results and its outlook for 2019.

The call will be hosted by Erez Raphael, Chief Executive Officer, Olivier Jarry, President and Chief Commercial Officer, and Zvi Ben-David, Chief Financial Officer.

The live call can be accessed by dialing 1-844-369-8770 or 1-862-298-0840 (international). Participants should ask for the DarioHealth Earnings Conference Call. The conference call will also be available via live webcast at: https://www.investornetwork.com/event/presentation/54487

Conference Call Details:

Date: Tuesday, October 28, 2019

Time: 9:00am EDT

Dial-in Number: 1-844-369-8770

International Dial-in Number: 1-862-298-0840

Webcast: www.investornetwork.com/event/presentation/54487

Participants are asked to dial-in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through November 11, 2019. To listen to the replay, dial 1-877-481-4010 (domestic) or 1-919-882-2331 (international) and use replay passcode 54487. The webcast replay will be available through January 28, 2020.

About DarioHealth Corp.

DarioHealth Corp. (DRIO) is a leading Global Digital Therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by precision data analytics, high quality software, and personalized coaching, DarioHealth have developed a novel approach that empowers individuals to adjust their lifestyle in a unique and holistic way. DarioHealth's cross functional team operates at the intersection of life science, behavioral science, and software technology to deliver seamlessly integrated and highly engaging therapeutic interventions. Already one of the highest rated diabetes solutions, its user-centric approach is loved by tens of thousands of customers around the globe. DarioHealth is rapidly expanding solutions for additional chronic conditions such as hypertension and moving into new geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions via the Dario mobile app, please go to: https://www.dariohealth.com/.

DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
[e-mail]
[phone]

[1vman]

*****Yup Dario is always appointing someone yet they cant seem to get pps up

Terribly run company here !


More to say !

[ProfitScout]

Exceptional new addition to the DRIO leadership team announced this week. I am sure Dr. Abigail Hirsch will make significant contributions to the work that Dario is doing to raise the level of healthcare for the growing number of patients which the company serves around the world.

Note the comments from the news:

"Dr. Hirsch has an impressive track record of successfully advancing the development of digital therapeutic programs in the health tech industry. She brings her extensive experience to DarioHealth's digital chronic condition management platform. This is particularly relevant because of the behavioral components in our platform which integrate data collection and analytics with coaching and digital lifestyle management. We expect Dario will benefit greatly from her unique perspective and guidance as she helps shape our position in the field of chronic condition management," said Erez Raphael, CEO.

Dr. Hirsch added, "I love Dario's solution and am very excited to be joining their team. Dario's unique digital therapeutics platform is distinguished by its client-centered approach. This facet of the technology has proven successful in engaging users to better manage their health. I look forward to working closely with the Dario team as we further penetrate the B2B market with solutions that advance the management of chronic conditions while positively impacting patients, providers and payers."

[HSTallday76]

Definitely good news

[jedijazz]

***$DRIO In This week's News #Nasdaq's DarioHealth Appoints Digital Therapeutics Pioneer Dr. Abigail Hirsch to Its Advisory Board to Support Commercial Strategy and Execution***
https://dariohealth.investorroom.com/2019-10-22-DarioHealth-Appoints-Digital-Therapeutics-Pioneer-Dr-Abigail-Hirsch-to-Its-Advisory-Board-to-Support-Commercial-Strategy-and-Execution

[1vman]

*****Buyer beware ! Another reverse split_coming_soon_for this junk to remain on the NASDAQ

[StockHighAlert-]

Dr. Hirsch has many years of experience utilizing clinical psychology, data analytics and educational design to create innovative healthcare technology that helps people lead healthier, more fulfilling lives.

Prior to joining Dario, Dr. Hirsch served as Chief Clinical Officer at a behavioral health company called myStrength, helping lead the company from inception through its acquisition by Livongo Health, Inc. in the first quarter of 2019. She holds a Ph.D. in Clinical Psychology from the University of Massachusetts.

[StockHighAlert-]

"Dr. Hirsch has an impressive track record of successfully advancing the development of digital therapeutic programs in the health tech industry. She brings her extensive experience to DarioHealth's digital chronic condition management platform. This is particularly relevant because of the behavioral components in our platform which integrate data collection and analytics with coaching and digital lifestyle management. We expect Dario will benefit greatly from her unique perspective and guidance as she helps shape our position in the field of chronic condition management," said Erez Raphael, CEO.

[StockHighAlert-]

Dr. Hirsch added, "I love Dario's solution and am very excited to be joining their team. Dario's unique digital therapeutics platform is distinguished by its client-centered approach. This facet of the technology has proven successful in engaging users to better manage their health. I look forward to working closely with the Dario team as we further penetrate the B2B market with solutions that advance the management of chronic conditions while positively impacting patients, providers and payers."

[StockHighAlert-]

$DRIO DarioHealth Appoints Digital Therapeutics Pioneer Dr. Abigail Hirsch to Its Advisory Board to Support Commercial Strategy and Execution https://finance.yahoo.com/news/dariohealth-appoints-digital-therapeutics-pioneer-120300884.html

[jedijazz]

DarioHealth Corporat (DRIO) 0.269 +0.019 (7.60%)

[jedijazz]

$DRIO News: DarioHealth Appoints Digital Therapeutics Pioneer Dr. Abigail Hirsch to Its Advisory Board to Support Commercial Strategy and Execution

PR Newswire•October 22, 2019

CAESAREA, Israel and NEW YORK, Oct. 22, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, has appointed Dr. Abigail Hirsch to its Advisory Board where she will help guide commercial and Business-to-Business (B2B) efforts.

Dario Health (PRNewsfoto/DarioHealth Corp.)

Dr. Hirsch has many years of experience utilizing clinical psychology, data analytics and educational design to create innovative healthcare technology that helps people lead healthier, more fulfilling lives.

Prior to joining Dario, Dr. Hirsch served as Chief Clinical Officer at a behavioral health company called myStrength, helping lead the company from inception through its acquisition by Livongo Health, Inc. in the first quarter of 2019. She holds a Ph.D. in Clinical Psychology from the University of Massachusetts.

"Dr. Hirsch has an impressive track record of successfully advancing the development of digital therapeutic programs in the health tech industry. She brings her extensive experience to DarioHealth's digital chronic condition management platform. This is particularly relevant because of the behavioral components in our platform which integrate data collection and analytics with coaching and digital lifestyle management. We expect Dario will benefit greatly from her unique perspective and guidance as she helps shape our position in the field of chronic condition management," said Erez Raphael, CEO.

Dr. Hirsch added, "I love Dario's solution and am very excited to be joining their team. Dario's unique digital therapeutics platform is distinguished by its client-centered approach. This facet of the technology has proven successful in engaging users to better manage their health. I look forward to working closely with the Dario team as we further penetrate the B2B market with solutions that advance the management of chronic conditions while positively impacting patients, providers and payers."

About DarioHealth Corp.

DarioHealth Corp. (DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™ mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, please go to: http://mydario.com/.

[ProfitScout]

I am looking forward to the upcoming DRIO conference all on October 28th and it is clear that other investors are as well from the buying in the stock taking place. We know this company has so many positive developments in play and a strong business plan for the future to discuss. It is also very reassuring to note that DRIO insiders hold a large stake in the company and have even been adding to their positions recently.

DarioHealth Corp. (NASDAQ: DRIO) is a leading Global Digital Therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by precision data analytics, high quality software, and personalized coaching, DarioHealth have developed a novel approach that empowers individuals to adjust their lifestyle in a unique and holistic way. DarioHealth's cross functional team operates at the intersection of life science, behavioral science, and software technology to deliver seamlessly integrated and highly engaging therapeutic interventions. Already one of the highest rated diabetes solutions, its user-centric approach is loved by tens of thousands of customers around the globe. DarioHealth is rapidly expanding solutions for additional chronic conditions such as hypertension and moving into new geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions via the Dario mobile app, please go to: https://www.dariohealth.com/.

[jedijazz]

$DRIO .261 +3.08% up on news this week as DarioHealth to Host Third Quarter 2019 Conference Call on October 28, 2019 http://www.prnewswire.com/news-releases/dariohealth-to-host-third-quarter-2019-conference-call-october-28-2019-300940365.html